Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it.

782 FDA drug recalls with this cause, newest first.

Cross-contamination means a product picked up traces of a different drug during manufacturing, repackaging or handling - usually because equipment or a facility was shared. Penicillin is the classic case: it is a potent allergen, so FDA requires it to be made in fully separate facilities, and a single lapse can put every product that passed through the same line on the recall list. Most of these recalls are precautionary sweeps of everything a firm handled during the affected period, which is why one event can add hundreds of entries at once.

Total recalls
782
Class I (high risk)
11
Currently ongoing
24
Most recent
Aug 18, 2026

Most-cited firms for this cause

  • Attix Pharmaceuticals466
  • Sage Products Inc64
  • the Compounder47
  • Life Science Pharmacy Inc23
  • Terra-Medica Inc.22
  • South Coast Specialty Compounding, Inc.15
  • Zydus Pharmaceuticals USA Inc14
  • Alvogen, Inc9
Class I · High risk

Cetirizine Hydrochloride Tablets USP 5 mg

Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

Ongoing Cross-contamination JB Chemicals and Pharmaceuticals Ltd NDC 16571-401-10 D-0732-2026
Class III · Low risk

Primidone Tablets

Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.

Ongoing Cross-contamination Amneal Pharmaceuticals, LLC D-0585-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Amerisource Health Services LLC D-0537-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Amerisource Health Services LLC D-0536-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Golden State Medical Supply Inc. NDC 51407-638-01 D-0535-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Golden State Medical Supply Inc. NDC 51407-637-05 D-0534-2026
Class III · Low risk

Primidone Tablets USP

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Lannett Company Inc. NDC 0527-1231-01 D-0533-2026
Class III · Low risk

Nebivolol Tablets

Cross Contamination with Other Products

Ongoing Cross-contamination Glenmark Pharmaceuticals Inc., USA NDC 42291-874-90 D-0222-2026
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-011-13 D-0469-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-009-13 D-0468-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-008-13 D-0467-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-007-13 D-0466-2024
Class III · Low risk

Digoxin Tablets

Cross Contamination with Other Products:(mycophenolate mofetil).

Terminated Cross-contamination Novitium Pharma LLC NDC 70954-201-20 D-0389-2024
Class I · High risk

Brexafemme

Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).

Completed Cross-contamination Scynexis, Inc. NDC 75788-115-04 D-0042-2024